Traduction de «Exposure-time marking » (Anglais → Français) :

exposure duration [ duration of exposure | exposure time | time of exposure | contact period ]

exposure [ exposure time | period of exposure | length of exposure ]

exposure time to radiation | exposure time

exposure time | time of exposure

exposure time setting ring [ exposure setting ring ]

exposure time

exposure time

T. whereas migration towards the EU is only part of a much broader South-North and South-South migratory phenomenon; whereas the geographical proximity to the EU of European Neighbourhood Policy (ENP) countries and, at the same time, the marked difference in standards between the migration laws of some ENP countries and those of the EU can create a competitive advantage for those countries, reinforcing their standing as transit countries and limiting their exposure and responsibilities as potential receiving countries,

T. whereas migration towards the EU is only part of a much broader South-North and South-South migratory phenomenon; whereas the geographical proximity to the EU of European Neighbourhood Policy (ENP) countries and, at the same time, the marked difference in standards between the migration laws of some ENP countries and those of the EU can create a competitive advantage for those countries, reinforcing their standing as transit countries and limiting their exposure and responsibilities as potential receiving countries,

T. whereas migration towards the EU is only part of a much broader South-North and South-South migratory phenomenon; whereas the geographical proximity to the EU of European Neighbourhood Policy (ENP) countries and, at the same time, the marked difference in standards between the migration laws of some ENP countries and those of the EU can create a competitive advantage for those countries, reinforcing their standing as transit countries and limiting their exposure and responsibilities as potential receiving countries,

Q-26 — Mr. Cummins (Delta—South Richmond) — With regard to the risk management of the antimalarial drug mefloquine by Health Canada and the Department of National Defence: (a) what deployments since 1990 involved administration of the drug to members of the Canadian Forces; (b) did Health Canada receive from the Canadian Forces adverse drug event reports for each such deployment either during or immediately following deployment; (c) how many Canadians received the drug under Health Canada’s Lariam Safety Monitoring Study; (d) how many patients were the subject of monitoring reports received by Health Canada directly or indirectly from Roche under the Lariam Safety Monitoring Study; (e) what types of adverse events were identified by the ...[+++] Lariam Safety Monitoring Study up to the time the drug was licensed in 1993; (f) what is the total number of adverse events reported to Health Canada since the commencement of marketing in 1993; (g) how many adverse events were reported to Health Canada since the commencement of the marketing of the drug in 1993 involving each of the following reactions - hallucinations, panic reaction, hyper alertness, extreme excitability, convulsions, aggressive reaction, marked restlessness, suicide, suicidal tendency, suicide attempt, thoughts of self harm, abnormal dreams, emotional disorder, irritability, nightmares, abnormal thinking, anxiety, depressed state, aggravated depression, light-headedness, anxiety attack, mood swings, abnormal crying, psychosis, delusion, speech disorder, concentration impaired, fear, euphoria, hysteria, paranoid psychosis, memory impairment, emotional disorder, murder; (h) what measures have been taken by Health Canada to ensure that it receives notice of such adverse drug events from doctors administering the drug; (i) what changes to the product monograph have been approved by Health Canada since licensing of the drug in 1993; (j) how many Canadian Forces members deployed on special missions abroad sinc ...